Galvus
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Galvus (vildagliptin; Novartis) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels.
The franchise product Eucreas ([vildagliptin + metformin]; Novartis) addresses the fact that Galvus is generally used as a second- or third-line treatment option as an add-on to metformin.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Galvus : Diabetes type 2
LIST OF FIGURES
9 Figure 1: Galvus brand franchise for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of Galvus
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for Galvus compared to Januvia
13 Figure 4: Galvus sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
15 Figure 5: Eucreas sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Galvus franchise products
5 Table 2: Galvus drug profile
5 Table 3: Eucreas drug profile
6 Table 4: Overview of pivotal trial data for Galvus franchise in diabetes
14 Table 5: Galvus sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
16 Table 6: Eucreas sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Glyxambi 
Sign up to the